EP0254272A3 - The use of probucol for preventing and treating heart diseases - Google Patents

The use of probucol for preventing and treating heart diseases Download PDF

Info

Publication number
EP0254272A3
EP0254272A3 EP87110551A EP87110551A EP0254272A3 EP 0254272 A3 EP0254272 A3 EP 0254272A3 EP 87110551 A EP87110551 A EP 87110551A EP 87110551 A EP87110551 A EP 87110551A EP 0254272 A3 EP0254272 A3 EP 0254272A3
Authority
EP
European Patent Office
Prior art keywords
probucol
preventing
treating heart
heart diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87110551A
Other versions
EP0254272A2 (en
EP0254272B1 (en
Inventor
Aloys Dr. Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Priority to AT87110551T priority Critical patent/ATE104142T1/en
Publication of EP0254272A2 publication Critical patent/EP0254272A2/en
Publication of EP0254272A3 publication Critical patent/EP0254272A3/en
Application granted granted Critical
Publication of EP0254272B1 publication Critical patent/EP0254272B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of probucol for preventing and treating heart diseases, wherein a reduced myocardial oxygen consumption is desirable or necessary, such as cardiomyopathy of various origins, the hyperkinetic heart syndrome and coronary heart disease, including coronary insufficiency and its concomitant symptoms or secondary diseases.
EP87110551A 1986-07-25 1987-07-21 The use of probucol for preventing and treating heart diseases Expired - Lifetime EP0254272B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87110551T ATE104142T1 (en) 1986-07-25 1987-07-21 USE OF PROBUCOL FOR PREVENTION AND TREATMENT OF HEART DISEASE.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3625279 1986-07-25
DE19863625279 DE3625279A1 (en) 1986-07-25 1986-07-25 USE OF PROBUCOL FOR THE PREVENTION AND TREATMENT OF HEART DISEASES

Publications (3)

Publication Number Publication Date
EP0254272A2 EP0254272A2 (en) 1988-01-27
EP0254272A3 true EP0254272A3 (en) 1989-11-23
EP0254272B1 EP0254272B1 (en) 1994-04-13

Family

ID=6306020

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87110551A Expired - Lifetime EP0254272B1 (en) 1986-07-25 1987-07-21 The use of probucol for preventing and treating heart diseases

Country Status (5)

Country Link
EP (1) EP0254272B1 (en)
JP (1) JPS63107915A (en)
AT (1) ATE104142T1 (en)
DE (2) DE3625279A1 (en)
ES (1) ES2054633T3 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517232A (en) * 1997-03-24 2001-10-02 コート，ジル Vascular remodeling agent
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
BR9809819A (en) 1997-05-14 2001-09-18 Atherogenics Inc Compounds and methods for inhibiting vcam-1 expression
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EP1272465A2 (en) 2000-04-11 2003-01-08 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
BRPI0809423A2 (en) 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc USES AND COMPOSITIONS OF PROBUCOL DERIVATIVES FOR TREATMENT OF DIABETES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US960003A (en) * 1909-09-11 1910-05-31 Alexander F Divok Folding steps.
EP0212310A2 (en) * 1985-08-23 1987-03-04 Merrell Dow Pharmaceuticals Inc. Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US960003A (en) * 1909-09-11 1910-05-31 Alexander F Divok Folding steps.
EP0212310A2 (en) * 1985-08-23 1987-03-04 Merrell Dow Pharmaceuticals Inc. Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARTERY, vol. 10, no. 1, 1982, pages 22-34; R.E. TEDESCHI et al.: "Safety and effectiveness of probucol as a cholesterol lowering agent" *
ARTERY, vol. 10, no. 1, 1982, pages 35-43; T.A. MIETTINEN et al.: "Clinical experience with probucol with special emphasis on mode of action and long-term treatment" *
CHEM-ENG. NEWS, vol. 60, no. 28, 12th July 1982, pages 26-38; H.J. SANDERS: "New drugs for combating heart disease" *
J. OCCUP. MED., vol. 23, no. 3, 1981, pages 202-209; G.C. TIMMIS: "Medical management of ischemic heart disease" *
JAMA, vol. 254, no. 15, 1985, pages 2097-2102; T.A. MIETTINEN et al.: "Multifactorial primary prevention of cardiovascular diseases in middle-aged men" *
THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 49, / 4II, 1982, page 914; M.J. BARBER et al.: "Effect of probucol on left ventricular myocardial blood flow during sympathetic nerve stimulation and maximal coronary vasodilation" *

Also Published As

Publication number Publication date
EP0254272A2 (en) 1988-01-27
ATE104142T1 (en) 1994-04-15
ES2054633T3 (en) 1994-08-16
DE3625279A1 (en) 1988-02-04
JPS63107915A (en) 1988-05-12
DE3789579D1 (en) 1994-05-19
DE3789579T2 (en) 1994-10-13
EP0254272B1 (en) 1994-04-13

Similar Documents

Publication Publication Date Title
OA08581A (en) Treatment of diseases caused by retroviruses.
EP0222330A3 (en) N6-substituted-5'-oxidized adenosine analogs
GR860571B (en) Labdan-derivatives process for their preparation and their use as medicaments
EP0273277A3 (en) Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus
EP0571387A4 (en) A non-mitogenic competitive hgf antagonist
FI883300A0 (en) A process for the preparation of new therapeutically active benzothiophenes
EP0254272A3 (en) The use of probucol for preventing and treating heart diseases
HUT47427A (en) Bezafibrat for treating diabetes
EG18175A (en) Process for the preparing of compounds having a cognition adjuvant action, agents containing them and the use thereof in the treatment and prophylaxis of cognitive dysfunctions
EP0253146A3 (en) The use of d-fenfluramine for the manufacture of medicaments for treating depression
DE3879429D1 (en) CYCLOPROPANDERIVATES.
CA1262912C (en) Tetrahydrofuranyl substituted prostaglandin analogs
NO890681D0 (en) PROCEDURE FOR THE PREPARATION OF ALKANOYL AND AROYLOXAZOLONS.
EP0212310A3 (en) Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia
PT85602A (en) Oxolabdanes a process for their preparation and their use as medicaments
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
DE3775375D1 (en) USE OF ANIPAMIL AS AN ARTEREOSCLEROSIS.
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
DE295827T1 (en) USE OF 24,25-DIHYDROXYCHOLECALCIFEROL IN HEALING BONE BREAKS.
AU1162788A (en) Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19900425

17Q First examination report despatched

Effective date: 19910404

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 104142

Country of ref document: AT

Date of ref document: 19940415

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3789579

Country of ref document: DE

Date of ref document: 19940519

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2054633

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3012497

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 87110551.6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20020702

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20020703

Year of fee payment: 16

Ref country code: NL

Payment date: 20020703

Year of fee payment: 16

Ref country code: AT

Payment date: 20020703

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20020704

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20020709

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20020717

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20020723

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20020730

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20020802

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20020807

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030721

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030721

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030722

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030731

BERE Be: lapsed

Owner name: *MERRELL DOW PHARMACEUTICALS INC.

Effective date: 20030731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040205

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20030721

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040331

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20040201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050721